



## Natco Pharma Limited

Regd. Off. : 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad - 500034.  
Telangana, INDIA. Tel : +91 40 23547532, Fax : +91 40 23548243  
CIN : L24230TG1981PLC003201, www.natcopharma.co.in

May 31, 2022

Corporate Relationship Department  
M/s. BSE Ltd.  
Dalal Street, Fort  
Mumbai 400 001

Manager – Listing  
M/s. National Stock Exchange of India Ltd  
“Exchange Plaza”, Bandra – Kurla Complex  
Bandra (E) Mumbai 400 051

Scrip Code: 524816

Scrip Code: NATCOPHARM

Sub: - Paper publication – Audited Financial Results of the Company

Pursuant to Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, please find enclosed the copies of the newspaper Publication as appeared on 31<sup>st</sup> May, 2022 in Business Standard and Nava Telangana regarding Audited Financial Results of the Company for the quarter and year ended 31<sup>st</sup> March, 2022.

Thanking you

Yours faithfully  
For NATCO Pharma Limited

Ch. Venkat Ramesh  
Company Secretary &  
Compliance Officer

Encl: as above



# NATCO Pharma Limited

Regd. Office: NATCO HOUSE, Road No.2, Banjara Hills, Hyderabad-500 034

Phone : 040-23547532, Email : investors@natcopharma.co.in

CIN : L24230TG1981PLC003201 www.natcopharma.co.in

## Extract of Consolidated Audited Financial Results for the Quarter and Year Ended March 31, 2022

(All amounts in Indian Rupees millions)

Sl. No.	Particulars	Quarter Ended	Quarter Ended	Quarter Ended	Year Ended	Year Ended
		31/03/2022 Refer Note-4	31/12/2021 (Unaudited)	31/03/2021 Refer Note-4	31/03/2022 (Audited)	31/03/2021 (Audited)
1	Revenue from operations	5,968	5,605	3,313	19,448	20,521
2	Profit for the period (before tax, Exceptional and / or Extraordinary items)	(496)	910	707	2,022	5,796
3	Profit for the period before tax (after Exceptional and / or Extraordinary items)	(496)	910	707	2,022	5,796
4	Profit for the period after tax (after Exceptional and / or Extraordinary items) and non-controlling interests	(505)	804	530	1,700	4,409
5	Total Comprehensive Income for the period attributable to owners of the parent	(286)	1,082	600	2,197	4,496
6	Paid-up Equity Share Capital of Rs.2/- each	365	365	365	365	365
7	Other equity (Revaluation reserve Rs.Nil)				42,271	40,851
8	Earnings Per Share (in Rupees) per Rs.2/- share (non-annualised)					
	1) Basic	(2.77)	4.41	2.91	9.32	24.20
	2) Diluted	(2.77)	4.40	2.90	9.32	24.16

### Notes:

1. Summarized Audited Standalone Financial Results of the Company is as under

(All amounts in Indian Rupees millions)

Sl. No.	Particulars	Quarter Ended	Quarter Ended	Quarter Ended	Year Ended	Year Ended
		31/03/2022 Refer Note-4	31/12/2021 (Unaudited)	31/03/2021 Refer Note-4	31/03/2022 (Audited)	31/03/2021 (Audited)
1	Revenue from operations	5,141	5,295	3,115	17,678	16,535
2	Profit before Tax	(671)	797	734	1,559	3,922
3	Net Profit for the period / year	(613)	716	572	1,391	3,095
4	Total comprehensive income	(577)	1,020	635	1,795	3,228

2. The above is an extract of the detailed format of Financial Results for the quarter and year ended 31 March, 2022 filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015. The full format of the Quarterly and Annual Financial Results is available on the Stock Exchange website: [www.nseindia.com](http://www.nseindia.com) and [www.bseindia.com](http://www.bseindia.com) and also on the Company's website: [www.natcopharma.co.in](http://www.natcopharma.co.in)

3. The above financial results have been reviewed by the Audit Committee of the board and approved by the Board of Directors at their respective meeting held on 30 May, 2022

4. The results of the quarter ended 31 March, 2022 and 31 March, 2021 are balancing figures between audited figures in respect of the full financial years and the published unaudited year to date figures upto third quarter of the respective financial years. Also, the figures upto the end of third quarter were only reviewed and not subjected to audit.

Place: Hyderabad

Date: 30 May, 2022

for NATCO Pharma Limited

Sd/- V.C. Nannapaneni .

Managing Director



# NATCO Pharma Limited

Regd. Office: NATCO HOUSE, Road No.2, Banjara Hills, Hyderabad-500 034

Phone : 040-23547532, Email : investors@natcopharma.co.in

CIN : L24230TG1981PLC003201 www.natcopharma.co.in

Extract of Consolidated Audited Financial Results for the Quarter and Year Ended March 31, 2022

(All amounts in Indian Rupees millions)

Sl. No.	Particulars	Quarter Ended	Quarter Ended	Quarter Ended	Year Ended	Year Ended
		31/03/2022 Refer Note-4	31/12/2021 (Unaudited)	31/03/2021 Refer Note-4	31/03/2022 (Audited)	31/03/2021 (Audited)
1	Revenue from operations	5,968	5,605	3,313	19,448	20,521
2	Profit for the period (before tax, Exceptional and / or Extraordinary items)	(496)	910	707	2,022	5,796
3	Profit for the period before tax (after Exceptional and / or Extraordinary items)	(496)	910	707	2,022	5,796
4	Profit for the period after tax (after Exceptional and / or Extraordinary items) and non-controlling interests	(505)	804	530	1,700	4,409
5	Total Comprehensive Income for the period attributable to owners of the parent	(286)	1,082	600	2,197	4,496
6	Paid-up Equity Share Capital of Rs.2/- each	365	365	365	365	365
7	Other equity (Revaluation reserve: Rs Nil)				42,271	40,851
8	Earnings Per Share (in Rupees) per Rs.2/- share (non-annualised)					
	1) Basic	(2.77)	4.41	2.91	9.32	24.20
	2) Diluted	(2.77)	4.40	2.90	9.32	24.16

#### Notes:

1. Summarized Audited Standalone Financial Results of the Company is as under

(All amounts in Indian Rupees millions)

Sl. No.	Particulars	Quarter Ended	Quarter Ended	Quarter Ended	Year Ended	Year Ended
		31/03/2022 Refer Note-4	31/12/2021 (Unaudited)	31/03/2021 Refer Note-4	31/03/2022 (Audited)	31/03/2021 (Audited)
1	Revenue from operations	5,141	5,295	3,115	17,678	16,535
2	Profit before Tax	(671)	797	734	1,559	3,922
3	Net Profit for the period / year	(613)	716	572	1,391	3,095
4	Total comprehensive income	(577)	1,020	635	1,795	3,228

2. The above is an extract of the detailed format of Financial Results for the quarter and year ended 31 March, 2022 filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015. The full format of the Quarterly and Annual Financial Results is available on the Stock Exchange website: [www.nseindia.com](http://www.nseindia.com) and [www.bseindia.com](http://www.bseindia.com) and also on the Company's website: [www.natcopharma.co.in](http://www.natcopharma.co.in)

3. The above financial results have been reviewed by the Audit Committee of the board and approved by the Board of Directors at their respective meeting held on 30 May, 2022.

4. The results of the quarter ended 31 March, 2022 and 31 March, 2021 are balancing figures between audited figures in respect of the full financial years and the published unaudited year to date figures upto third quarter of the respective financial years. Also, the figures upto the end of third quarter were only reviewed and not subjected to audit.

Place: Hyderabad

Date: 30 May, 2022

for NATCO Pharma Limited

Sd/- V.C. Nannapaneni

Managing Director